These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 19281242)

  • 1. Anti-amyloid activity of the C-terminal domain of proSP-C against amyloid beta-peptide and medin.
    Nerelius C; Gustafsson M; Nordling K; Larsson A; Johansson J
    Biochemistry; 2009 May; 48(17):3778-86. PubMed ID: 19281242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations linked to interstitial lung disease can abrogate anti-amyloid function of prosurfactant protein C.
    Nerelius C; Martin E; Peng S; Gustafsson M; Nordling K; Weaver T; Johansson J
    Biochem J; 2008 Dec; 416(2):201-9. PubMed ID: 18643778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventing amyloid formation by catching unfolded transmembrane segments.
    Johansson H; Nerelius C; Nordling K; Johansson J
    J Mol Biol; 2009 Jun; 389(2):227-9. PubMed ID: 19376131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-terminal, endoplasmic reticulum-lumenal domain of prosurfactant protein C - structural features and membrane interactions.
    Casals C; Johansson H; Saenz A; Gustafsson M; Alfonso C; Nordling K; Johansson J
    FEBS J; 2008 Feb; 275(3):536-47. PubMed ID: 18199284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amino acid sequence determinants and molecular chaperones in amyloid fibril formation.
    Nerelius C; Fitzen M; Johansson J
    Biochem Biophys Res Commun; 2010 May; 396(1):2-6. PubMed ID: 20494101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide-binding specificity of the prosurfactant protein C Brichos domain analyzed by electrospray ionization mass spectrometry.
    Fitzen M; Alvelius G; Nordling K; Jörnvall H; Bergman T; Johansson J
    Rapid Commun Mass Spectrom; 2009 Nov; 23(22):3591-8. PubMed ID: 19844966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure and influence on stability and activity of the N-terminal propeptide part of lung surfactant protein C.
    Li J; Liepinsh E; Almlén A; Thyberg J; Curstedt T; Jörnvall H; Johansson J
    FEBS J; 2006 Mar; 273(5):926-35. PubMed ID: 16478467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The BRICHOS domain, amyloid fibril formation, and their relationship.
    Knight SD; Presto J; Linse S; Johansson J
    Biochemistry; 2013 Oct; 52(43):7523-31. PubMed ID: 24099305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formation of highly toxic soluble amyloid beta oligomers by the molecular chaperone prefoldin.
    Sakono M; Zako T; Ueda H; Yohda M; Maeda M
    FEBS J; 2008 Dec; 275(23):5982-93. PubMed ID: 19021772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide and protein mimetics inhibiting amyloid beta-peptide aggregation.
    Takahashi T; Mihara H
    Acc Chem Res; 2008 Oct; 41(10):1309-18. PubMed ID: 18937396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRICHOS domain associated with lung fibrosis, dementia and cancer--a chaperone that prevents amyloid fibril formation?
    Willander H; Hermansson E; Johansson J; Presto J
    FEBS J; 2011 Oct; 278(20):3893-904. PubMed ID: 21668643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The intact human acetylcholinesterase C-terminal oligomerization domain is alpha-helical in situ and in isolation, but a shorter fragment forms beta-sheet-rich amyloid fibrils and protofibrillar oligomers.
    Cottingham MG; Voskuil JL; Vaux DJ
    Biochemistry; 2003 Sep; 42(36):10863-73. PubMed ID: 12962511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro characterization of lactoferrin aggregation and amyloid formation.
    Nilsson MR; Dobson CM
    Biochemistry; 2003 Jan; 42(2):375-82. PubMed ID: 12525164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of beta-amyloid peptide aggregation and neurotoxicity by alpha-d-mannosylglycerate, a natural extremolyte.
    Ryu J; Kanapathipillai M; Lentzen G; Park CB
    Peptides; 2008 Apr; 29(4):578-84. PubMed ID: 18304694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers.
    Robert R; Dolezal O; Waddington L; Hattarki MK; Cappai R; Masters CL; Hudson PJ; Wark KL
    Protein Eng Des Sel; 2009 Mar; 22(3):199-208. PubMed ID: 18927231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An intersheet packing interaction in A beta fibrils mapped by disulfide cross-linking.
    Shivaprasad S; Wetzel R
    Biochemistry; 2004 Dec; 43(49):15310-7. PubMed ID: 15581343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction between synthetic amyloid-beta-peptide (1-40) and its aggregation inhibitors studied by electrospray ionization mass spectrometry.
    Skribanek Z; Baláspiri L; Mák M
    J Mass Spectrom; 2001 Nov; 36(11):1226-9. PubMed ID: 11747119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abeta protofibrils possess a stable core structure resistant to hydrogen exchange.
    Kheterpal I; Lashuel HA; Hartley DM; Walz T; Lansbury PT; Wetzel R
    Biochemistry; 2003 Dec; 42(48):14092-8. PubMed ID: 14640676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unwinding fibril formation of medin, the peptide of the most common form of human amyloid.
    Larsson A; Söderberg L; Westermark GT; Sletten K; Engström U; Tjernberg LO; Näslund J; Westermark P
    Biochem Biophys Res Commun; 2007 Oct; 361(4):822-8. PubMed ID: 17679143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-amyloid fibril formation is promoted by step edges of highly oriented pyrolytic graphite.
    Losic D; Martin LL; Aguilar MI; Small DH
    Biopolymers; 2006; 84(5):519-26. PubMed ID: 16752395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.